Chen’s study demonstrated that MR imaging based radiomic analysis of BM in patients with primary lung cancer may be used to classify EGFR, ALK, and KRAS mutation status and the AUC values based on cross validation was 0.912, 0.915, and 0.985, respectively (Chen et al., 2020b). This evidence concerns the gene KRAS and lung carcinoma.